BACKGROUND: Acute coronary syndrome is the most common cause of cardiac morbidity and death. Various scoring systems have been developed in order to identify patients who are at risk for adverse outcome and may benefit from more aggressive and effective therapies. OBJECTIVES: This study was designed to evaluate the CHA2DS2VASC score as a predictor of mortality inpatients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (p-PCI). METHODS: We evaluated 300 patients diagnosed with ST-elevation myocardial infarction who underwent p-PCI and calculated their CHA2DS2VASC scores. According to their CHA2DS2VASC scores, patients were divided into three groups. Group 1: 0-1 points (n = 101), Group 2: 2-3 points (n = 129), and Group 3: 4-9 points (n = 70). The mean, median and minimum duration of follow-up were 21.7 ± 9.4, 21, and 12 months, respectively. All-cause mortality was defined as the primary endpoint of the study. RESULTS: All-cause mortality was 4% in Group 1, 8.5% in Group 2 and 27.1% in Group 3 respectively. Kaplan-Meier analysis showed that Group 3 (CHA2DS2VASC ≥ 4) had a significantly higher incidence of death [p (log-rank) < 0.001]. In ROC analysis, AUC values for in hospital, 12-month and long-term mortality were 0.88 (0.77-0.99 95% CI), 0.82 (0.73-0.92 95% CI) and 0.79 (0.69-0.88 95% CI), respectively. CONCLUSIONS: CHA2DS2VASC score can be used for predicting both in-hospital, 12-month and long-term mortality in patients with STEMI who have undergone p-PCI.
BACKGROUND: Acute coronary syndrome is the most common cause of cardiac morbidity and death. Various scoring systems have been developed in order to identify patients who are at risk for adverse outcome and may benefit from more aggressive and effective therapies. OBJECTIVES: This study was designed to evaluate the CHA2DS2VASC score as a predictor of mortality inpatients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (p-PCI). METHODS: We evaluated 300 patients diagnosed with ST-elevation myocardial infarction who underwent p-PCI and calculated their CHA2DS2VASC scores. According to their CHA2DS2VASC scores, patients were divided into three groups. Group 1: 0-1 points (n = 101), Group 2: 2-3 points (n = 129), and Group 3: 4-9 points (n = 70). The mean, median and minimum duration of follow-up were 21.7 ± 9.4, 21, and 12 months, respectively. All-cause mortality was defined as the primary endpoint of the study. RESULTS: All-cause mortality was 4% in Group 1, 8.5% in Group 2 and 27.1% in Group 3 respectively. Kaplan-Meier analysis showed that Group 3 (CHA2DS2VASC ≥ 4) had a significantly higher incidence of death [p (log-rank) < 0.001]. In ROC analysis, AUC values for in hospital, 12-month and long-term mortality were 0.88 (0.77-0.99 95% CI), 0.82 (0.73-0.92 95% CI) and 0.79 (0.69-0.88 95% CI), respectively. CONCLUSIONS: CHA2DS2VASC score can be used for predicting both in-hospital, 12-month and long-term mortality in patients with STEMI who have undergone p-PCI.
Authors: Line Melgaard; Anders Gorst-Rasmussen; Deidre A Lane; Lars Hvilsted Rasmussen; Torben Bjerregaard Larsen; Gregory Y H Lip Journal: JAMA Date: 2015-09-08 Impact factor: 56.272
Authors: Harmony R Reynolds; Sandra A Forman; Jacqueline E Tamis-Holland; Philippe Gabriel Steg; Daniel B Mark; Camille A Pearte; Antonio C Carvalho; George Sopko; Li Liu; Gervasio A Lamas; Mariusz Kruk; Krystyna Loboz-Grudzien; Witold Ruzyllo; Judith S Hochman Journal: Am Heart J Date: 2012-03 Impact factor: 4.749
Authors: Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: F Gustafsson; L Køber; C Torp-Pedersen; P Hildebrandt; M M Ottesen; B Sonne; J Carlsen Journal: Eur Heart J Date: 1998-04 Impact factor: 29.983
Authors: L Brent Mitchell; Danielle A Southern; Diane Galbraith; William A Ghali; Merril Knudtson; Stephen B Wilton Journal: Heart Date: 2014-05-23 Impact factor: 5.994
Authors: Alvaro Avezum; Marcia Makdisse; Frederick Spencer; Joel M Gore; Keith A A Fox; Gilles Montalescot; Kim A Eagle; Kami White; Rajendra H Mehta; Elias Knobel; Jean-Philippe Collet Journal: Am Heart J Date: 2005-01 Impact factor: 4.749
Authors: Kyung Hwan Kim; Wan Kim; Sun Ho Hwang; Won Yu Kang; Sang Cheol Cho; Weon Kim; Myung Ho Jeong Journal: J Cardiol Date: 2014-06-24 Impact factor: 3.159
Authors: Brian D Adkins; Hila Shaim; Abdul Abid; Adam Gonzalez; Abe DeAnda; Sean G Yates Journal: J Thromb Thrombolysis Date: 2022-06-14 Impact factor: 2.300